查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1732961

肝炎诊断检测市场－全球产业规模、份额、趋势、机会和预测（按检测类型、地区和竞争细分，2020-2030 年）

Hepatitis Diagnostic Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球肝炎诊断测试市场价值为 45.8 亿美元，预计到 2030 年将达到 65.1 亿美元，预测期内复合年增长率为 6.04%。全球性内肝炎（尤其是B型肝炎和C肝）的盛行率不断上升，推动了对准确、及时的诊断解决方案的需求。根据世界卫生组织统计，2021 年全球有近 3.25 亿人患有慢性肝炎，凸显了对有效诊断干预措施的迫切需求。这个市场受到人们意识的提高、技术进步以及早期检测以预防肝硬化和癌症等併发症的重要性的推动。各种检测方法（包括血清学、分子检测和肝功能检测）的出现拓宽了诊断能力。此外，创新的即时检验（POCT）设备使诊断变得更加容易，特别是在偏远或服务不足的地区。这些进步，加上政府措施和全球健康运动的加强，持续支撑市场的成长轨迹。

市场概览
预测期 2026-2030
2024年市场规模 45.8亿美元
2030年市场规模 65.1亿美元
2025-2030 年复合年增长率 6.04%
成长最快的领域 血液检查
最大的市场 北美洲

关键市场驱动因素

全球肝炎负担不断上升

主要市场挑战

高昂的诊断费用

主要市场趋势

即时检验 (POCT)

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球肝炎诊断检验市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依测试类型（血液检查、影像学检查、肝臟活检）
    • 按地区（北美、欧洲、亚太、南美、中东和非洲）
    • 按公司分类（2024）
  • 产品市场图
    • 按测试类型
    • 按地区

第六章：北美肝炎诊断检验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章：欧洲肝炎诊断检验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区肝炎诊断检测市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲

第九章：南美洲肝炎诊断检验市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第十章：中东和非洲肝炎诊断测试市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA：国家分析
    • 阿联酋
    • 沙乌地阿拉伯
    • 南非

第 11 章：市场动态

  • 驱动程式
  • 挑战

第 12 章：市场趋势与发展

  • 合併与收购
  • 产品开发
  • 最新动态

第 13 章：波特的分析

第 14 章：PESTEL 分析

第 15 章：竞争格局

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen NV
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

第 16 章：策略建议

第 17 章：关于我们与免责声明

简介目录
Product Code: 16280

The Global Hepatitis Diagnostic Test Market was valued at USD 4.58 billion in 2024 and is projected to reach USD 6.51 billion by 2030, growing at a CAGR of 6.04% during the forecast period. The increasing global prevalence of hepatitis, particularly Hepatitis B and C, is driving demand for accurate and timely diagnostic solutions. According to the World Health Organization, nearly 325 million individuals globally were living with chronic hepatitis in 2021, highlighting the urgent need for effective diagnostic interventions. This market is fueled by heightened awareness, technological advancements, and the importance of early detection to prevent complications like liver cirrhosis and cancer. The availability of various testing methods-including serology, molecular assays, and liver function tests-has broadened diagnostic capabilities. Furthermore, innovative point-of-care testing (POCT) devices are making diagnostics more accessible, especially in remote or underserved regions. These advancements, combined with increased government initiatives and global health campaigns, continue to bolster the market's growth trajectory.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.58 Billion
Market Size 2030USD 6.51 Billion
CAGR 2025-20306.04%
Fastest Growing SegmentBlood Tests
Largest MarketNorth America

Key Market Drivers

Rising Global Hepatitis Burden

The growing prevalence of hepatitis infections worldwide is a major force driving the Hepatitis Diagnostic Test Market. According to WHO, in 2023, approximately 60 million individuals in the South-East Asia region alone were living with chronic hepatitis B. Global transmission is often exacerbated by unsafe medical practices, lack of clean water and sanitation, and insufficient access to healthcare. Compounding this issue is the silent nature of hepatitis, which frequently progresses without symptoms until advanced liver damage has occurred. Early and accurate diagnosis is thus critical to preventing severe health outcomes such as cirrhosis and liver cancer. Governments and healthcare organizations are ramping up national screening programs and awareness campaigns, encouraging regular testing for high-risk populations including healthcare workers, people living with HIV, and intravenous drug users. These efforts are significantly expanding access to diagnostic services and promoting timely medical intervention.

Key Market Challenges

High Diagnostic Costs

A major challenge in the Hepatitis Diagnostic Test Market is the high cost associated with testing, particularly for molecular diagnostics such as PCR. These tests require specialized reagents, sophisticated equipment, and skilled laboratory personnel, which collectively drive up costs. This is especially burdensome in low-resource settings or among uninsured populations, where affordability becomes a barrier to widespread testing. Operational expenses tied to equipment maintenance, laboratory infrastructure, and quality assurance further increase the cost of diagnosis. Moreover, patients often require multiple tests to monitor disease progression and treatment efficacy, adding to the financial burden. In regions where insurance coverage is limited or inconsistent, out-of-pocket costs may deter individuals from undergoing necessary diagnostic evaluations.

Key Market Trends

Point-of-Care Testing (POCT)

Point-of-care testing is emerging as a transformative trend in hepatitis diagnostics. These compact, portable devices allow for rapid testing outside traditional laboratory environments, greatly enhancing diagnostic reach in rural and underserved areas. POCT minimizes the need for specialized equipment and skilled personnel, enabling quick, onsite diagnosis that facilitates timely treatment initiation. This immediacy not only improves patient outcomes but also helps curb the transmission of hepatitis within communities. The accessibility and speed of POCT make it a practical solution for widespread screening efforts, particularly in primary care settings and mobile health units. As healthcare providers seek more efficient and decentralized diagnostic methods, the adoption of POCT is expected to accelerate, driving market innovation and growth.

Key Market Players

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen N.V.
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

Report Scope:

In this report, the Global Hepatitis Diagnostic Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis Diagnostic Test Market, By Test Type:

  • Blood Tests
  • Imaging Test
  • Liver Biopsy

Hepatitis Diagnostic Test Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis Diagnostic Test Market.

Available Customizations:

Global Hepatitis Diagnostic Test market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis Diagnostic Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Blood Tests, Imaging Test, Liver Biopsy)
      • 5.2.1.1. By Blood Tests (Liver Function Tests, Immunoassays, Nucleic Acid Tests)
    • 5.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.3. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By Region

6. North America Hepatitis Diagnostic Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis Diagnostic Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
    • 6.3.2. Canada Hepatitis Diagnostic Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
    • 6.3.3. Mexico Hepatitis Diagnostic Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type

7. Europe Hepatitis Diagnostic Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatitis Diagnostic Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
    • 7.3.2. France Hepatitis Diagnostic Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
    • 7.3.3. United Kingdom Hepatitis Diagnostic Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
    • 7.3.4. Italy Hepatitis Diagnostic Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
    • 7.3.5. Spain Hepatitis Diagnostic Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type

8. Asia-Pacific Hepatitis Diagnostic Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hepatitis Diagnostic Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
    • 8.3.2. Japan Hepatitis Diagnostic Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
    • 8.3.3. India Hepatitis Diagnostic Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
    • 8.3.4. South Korea Hepatitis Diagnostic Test Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
    • 8.3.5. Australia Hepatitis Diagnostic Test Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type

9. South America Hepatitis Diagnostic Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hepatitis Diagnostic Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
    • 9.3.2. Argentina Hepatitis Diagnostic Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
    • 9.3.3. Colombia Hepatitis Diagnostic Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type

10. Middle East and Africa Hepatitis Diagnostic Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Hepatitis Diagnostic Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
    • 10.3.2. Saudi Arabia Hepatitis Diagnostic Test Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
    • 10.3.3. South Africa Hepatitis Diagnostic Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc
  • 15.3. F. Hoffmann-La Roche AG
  • 15.4. BioMerieux SA
  • 15.5. Siemens Healthineers
  • 15.6. Qiagen N.V.
  • 15.7. Grifols SA
  • 15.8. Fujirebio Inc.
  • 15.9. Molbio diagnostics Pvt. Ltd
  • 15.10. Meril LifeSciences Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimers